These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9668369)

  • 1. GM1 ganglioside in the treatment of Parkinson's disease.
    Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():363-73. PubMed ID: 9668369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
    Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
    Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
    Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
    Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM1 ganglioside in Parkinson's disease: Results of a five year open study.
    Schneider JS; Sendek S; Daskalakis C; Cambi F
    J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.
    Schneider JS; Gollomp SM; Sendek S; Colcher A; Cambi F; Du W
    J Neurol Sci; 2013 Jan; 324(1-2):140-8. PubMed ID: 23199590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.
    Schneider JS; Cambi F; Gollomp SM; Kuwabara H; Brašić JR; Leiby B; Sendek S; Wong DF
    J Neurol Sci; 2015 Sep; 356(1-2):118-23. PubMed ID: 26099170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganglioside GM1 in acute ischemic stroke. The SASS Trial.
    Stroke; 1994 Jun; 25(6):1141-8. PubMed ID: 8202971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass. Methodological strategies and results of a double-blind, placebo-controlled trial of GM1 ganglioside.
    Grieco G; d'Hollosy M; Culliford AT; Jonas S
    Stroke; 1996 May; 27(5):858-74. PubMed ID: 8623106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.
    Ba XH
    Int J Neurosci; 2016; 126(2):163-7. PubMed ID: 25495991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1997 Sep; 49(3):665-71. PubMed ID: 9305320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
    Schneider JS
    J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.
    Schneider JS
    Glycoconj J; 2022 Feb; 39(1):13-26. PubMed ID: 34037912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
    Wills AM; Li R; Pérez A; Ren X; Boyd J;
    J Neurol; 2017 Aug; 264(8):1746-1753. PubMed ID: 28712000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
    Wu G; Lu ZH; Kulkarni N; Ledeen RW
    J Neurosci Res; 2012 Oct; 90(10):1997-2008. PubMed ID: 22714832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo.
    Sommer BR; Cohen BM; Satlin A; Cole JO; Jandorf L; Dorsey F
    J Geriatr Psychiatry Neurol; 1994; 7(4):234-7. PubMed ID: 7826493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.